NCT01371656 · OUTCOME
Comparison of the Percentage of Patients Having Incidence of CDAD Between Arms
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percentage of patients
- Interval / dispersion
- Not reported
- Time frame
- Up to 60 days after enrollment or receiving levofloxacin
What was measured
Clostridium Difficile Associated Disease (CDAD) is defined as a positive C. difficile toxin assay result and diarrhea, CTCAE version 4, grade 2 and higher.
Analysis population: All evaluable, and centrally reviewed AL and HSCT patients are reported. Ineligible patients and patients who withdrew of consent prior to treatment were excluded.
Groups in this outcome
Arm I (Levofloxacin)
Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover. levofloxacin: Given PO or IV
Arm II (Standard of Care)
Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.
| Group | Source count |
|---|---|
| Arm I (Levofloxacin) | 306 |
| Arm II (Standard of Care) | 307 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm I (Levofloxacin) | 2.3 | Not reported | Not reported | Not reported | Not reported |
| Arm II (Standard of Care) | 5.2 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 2.3
- group Id
- OG001
- value
- 5.2
- denoms
- counts
- group Id
- OG000
- value
- 306
- group Id
- OG001
- value
- 307
- units
- Participants
- description
- Clostridium Difficile Associated Disease (CDAD) is defined as a positive C. difficile toxin assay result and diarrhea, CTCAE version 4, grade 2 and higher.
- groups
- description
- Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover. levofloxacin: Given PO or IV
- id
- OG000
- title
- Arm I (Levofloxacin)
- description
- Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.
- id
- OG001
- title
- Arm II (Standard of Care)
- param Type
- NUMBER
- population Description
- All evaluable, and centrally reviewed AL and HSCT patients are reported. Ineligible patients and patients who withdrew of consent prior to treatment were excluded.
- reporting Status
- POSTED
- time Frame
- Up to 60 days after enrollment or receiving levofloxacin
- title
- Comparison of the Percentage of Patients Having Incidence of CDAD Between Arms
- type
- SECONDARY
- unit Of Measure
- Percentage of patients
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle